Javascript must be enabled to continue!
Fistulating diverticulitis: a distinct clinical entity?
View through CrossRef
IntroductionDiverticular disease (DD) of the colon has a number of phenotypes, including asymptomatic diverticulosis and complicated diverticulitis with bowel perforation or bleeding. The factor that affects the phenotype of this condition and leads to a wide range of clinical presentations is unknown. The formation of fistulas associated with diverticulitis has long been recognized, and they are treated according to ad hoc indications. We hypothesized that the formation of fistulas in diverticular disease exhibits such a wide range of variable anatomic features that it may be considered a distinct form of the condition, fistulating diverticulitis (FD).MethodsWe conducted a narrative review based on 50 years of publications covering a wide range of diverticulitis-associated fistulas, both common and uncommon.ResultsWhile there is abundant literature on common fistulas, such as colovesical and colovaginal fistulas, little is known about rarer fistulas, such as coloenteric fistulas, colocutaneous fistulas, and genitourinary tract fistulas. The majority of these fistulas are treated surgically, which is in contrast to the trend toward conservative management that is predominant in acute or chronic diverticulitis.DiscussionEpidemiological and histological evidence support the hypothesis that FD may be a feature of chronic DD that requires individual management. Histopathology shows similarities with Crohn’s disease. It remains unknown which underlying immune or genetic factors may be affecting the clinical presentation of these patients, leading to fistulation. We contend that there is adequate published evidence to characterize a distinct phenotype of FD that can involve the entire GI tract and other organs. Surgical guidelines may need to be modified to treat this small but important group, which predominantly requires surgical treatment.
Frontiers Media SA
Title: Fistulating diverticulitis: a distinct clinical entity?
Description:
IntroductionDiverticular disease (DD) of the colon has a number of phenotypes, including asymptomatic diverticulosis and complicated diverticulitis with bowel perforation or bleeding.
The factor that affects the phenotype of this condition and leads to a wide range of clinical presentations is unknown.
The formation of fistulas associated with diverticulitis has long been recognized, and they are treated according to ad hoc indications.
We hypothesized that the formation of fistulas in diverticular disease exhibits such a wide range of variable anatomic features that it may be considered a distinct form of the condition, fistulating diverticulitis (FD).
MethodsWe conducted a narrative review based on 50 years of publications covering a wide range of diverticulitis-associated fistulas, both common and uncommon.
ResultsWhile there is abundant literature on common fistulas, such as colovesical and colovaginal fistulas, little is known about rarer fistulas, such as coloenteric fistulas, colocutaneous fistulas, and genitourinary tract fistulas.
The majority of these fistulas are treated surgically, which is in contrast to the trend toward conservative management that is predominant in acute or chronic diverticulitis.
DiscussionEpidemiological and histological evidence support the hypothesis that FD may be a feature of chronic DD that requires individual management.
Histopathology shows similarities with Crohn’s disease.
It remains unknown which underlying immune or genetic factors may be affecting the clinical presentation of these patients, leading to fistulation.
We contend that there is adequate published evidence to characterize a distinct phenotype of FD that can involve the entire GI tract and other organs.
Surgical guidelines may need to be modified to treat this small but important group, which predominantly requires surgical treatment.
Related Results
Development of an Ultrasound-Based Clinical Decision Rule to Rule-out Diverticulitis
Development of an Ultrasound-Based Clinical Decision Rule to Rule-out Diverticulitis
Abstract
The concern for diverticulitis often leads to the use of computed tomography (CT) scans for diagnosis. We aim to develop an ultrasound-based clinical decision rule...
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
Solitary cecal diverticulitis in a pediatric case: A challenging diagnosis
Solitary cecal diverticulitis in a pediatric case: A challenging diagnosis
Pediatric diverticulosis is a rare pathology. In Western countries, most cases of diverticulitis occur in the left colon. In contrast, the rate of right-sided diverticulitis is muc...
The Gastroenterologist’s View
The Gastroenterologist’s View
The traditional view that recurrent episodes of diverticulitis lead to progressively complicated disease resulting in a disadvantageous course, more difficult, complicated operatio...
Comprehensive Study of Diverticulitis: A Literature Review
Comprehensive Study of Diverticulitis: A Literature Review
Abstract: Diverticulitis is a symptomatic diverticular disease characterized by inflammation of the diverticulum. Until now, the pathophysiology of diverticulitis is not known with...
Microbiome Modulation After Bariatric Surgery: A Potential Link to Diverticulitis
Microbiome Modulation After Bariatric Surgery: A Potential Link to Diverticulitis
Background: Diverticulitis is an increasingly prevalent gastrointestinal condition in the United States, with rising incidence, recurrent disease burden, and significant morbidity....
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial
Introduction Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody in clinical development for the subcutaneous prophylactic treatment of hemophilia pati...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...

